Insights

Menin inhibitors represent a new frontier in treating relapsed/refractory acute myeloid leukemia (AML), but understanding the nuances between revumenib and ziftomenib is critical for clinical decision-making at the pharmacy bench. Join Sanja Zepcan, PharmD, BCPS, BCOP (Loyola Medicine), and Amir Ali, PharmD, BCOP (USC Norris), for a deep dive into mechanism of action, clinical trial data, label-level distinctions, and pharmacist-led strategies for initiation. This discussion equips pharmacists with the evidence and workflows needed to optimize therapy selection, catch drug interactions, counsel on the class-defining toxicity of differentiation syndrome, and navigate access barriers in this high-acuity patient population.

This expert-led series features Matthew Arango, PharmD, a specialty practice pharmacist in outpatient gastrointestinal oncology at The James Comprehensive Cancer Center at The Ohio State University Wexner Medical Center, providing an in-depth look at the evolving landscape of HER2-positive gastroesophageal adenocarcinoma (GEA). Across 8 segments, the series guides pharmacists and oncology care teams through the full continuum of care—from foundational disease understanding to cutting-edge therapies, patient-centered management, and interprofessional collaboration.

oHCM Insights: Best Practices for Clinical Pharmacists in Targeted CMI Therapy, features Andrew Willeford, PharmD, PhD, BCCP, and Laura Velazquez, PharmD, PhC, BCACP, in a peer-led conversation focused on optimizing management of obstructive hypertrophic cardiomyopathy (oHCM). The discussion centers on 3 themes: educating patients on the distinct pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and the targeted mechanism of cardiac myosin inhibitors (CMIs), particularly mavacamten and newly approved aficamten; aligning clinical decision-making with long-term clinical trial and real-world REMS data demonstrating sustained efficacy, safety, and appropriate echocardiographic monitoring; and defining the clinical pharmacist’s leadership role in multidisciplinary care. Emphasis is placed on differentiating oHCM from non-obstructive disease, reinforcing patient confidence through robust real-world evidence, navigating REMS requirements, screening for CYP2C19 and CYP3A4 drug–drug interactions (including OTC products), incorporating pharmacogenomic considerations, coordinating echocardiogram monitoring, managing insurance barriers, and reducing physician burden through proactive, system-level execution of CMI programs.

This educational Insights video series equips pharmacists with the latest evidence and recommendations surrounding adult pneumococcal vaccination. Drawing on new clinical data, updated CDC Advisory Committee on Immunization Practices guidance, and evolving public health considerations, this series breaks down how pneumococcal vaccine efficacy is measured, how recent approvals were supported by immunobridging data, and what today’s serotype landscape means for patient care. It also provides practical strategies for integrating the expanded age-based recommendations for adults 50 and older into routine workflow, immunization screening, and patient counseling.

In this video experts we will discuss key therapy updates and clinical considerations for the management of NSCLC.

The CDK4/6 Breast Cancer ESMO Insights Series brings together leading oncology pharmacy experts to break down the most impactful data shaping the future of HR-positive breast cancer care. Across this multi-part program, our panel examines pivotal updates from the monarchE, NATALEE, and VIKTORIA-1 trials—translating complex clinical findings into practical, actionable insights for clinicians. From adjuvant therapy outcomes to advances in the post–CDK4/6 inhibitor metastatic setting, this series is designed to help pharmacists and care teams understand how emerging evidence will influence treatment decisions and optimize care for patients across the disease continuum.

Panelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.

Rupal Mansukhani, PharmD, FAPhA, NCNTT, discusses how pneumococcal disease presents differently across age groups; identifies high-risk populations, including adults older than 50 years and immunocompromised patients; compares the 5 FDA-approved pneumococcal vaccines with emphasis on newer conjugate options like PCV20 and PCV21; and provides guidance for pharmacists on vaccine recommendations, addressing patient concerns and implementing effective follow-up systems to improve vaccination uptake and completion rates.

Carmen Janes, PharmD, BCOP, discusses how National Comprehensive Cancer Network guidelines inform first-line chronic myeloid leukemia (CML) treatment selection among tyrosine kinase inhibitors such as imatinib, nilotinib, and asciminib, emphasizing the importance of early molecular milestone achievement, proactive toxicity management, and the expanding role of pharmacists in optimizing patient adherence and quality of life through remote monitoring and medication access support.

A panelist discusses how pharmacists must be equipped with essential clinical knowledge, communication skills, and up-to-date information to administer RSV vaccines effectively, optimize vaccine uptake through patient education and hesitancy management, and respond appropriately to adverse events.

Cara Chang, PharmD, BCOP, provides comprehensive insights into the challenges, advances, and best practices in treating EGFR-positive non–small cell lung cancer (NSCLC), emphasizing the importance of molecular testing before treatment initiation, the evolution of targeted therapies and combination approaches, the critical role of pharmacists in medication management and patient education, and emerging treatments including subcutaneous amivantamab and antibody-drug conjugates that promise to improve outcomes while reducing toxicity.

Carrie Koenigsfeld, PharmD, FAPhA, discusses how pharmacists can lead efforts in vaccinating older adults against RSV by addressing barriers to vaccination, integrating education into pharmacy workflows, and implementing community outreach initiatives.

The discussion, led by Kirollos Hanna,PharmD, BCPS, BCOP, FACCC, and Brandon Dyson, PharmD, BCOP, BCPS, focuses on optimizing chronic lymphocytic leukemia care through the management of treatment modifications and adverse events, emphasizing pharmacists’ roles in patient education, dose adjustment strategies, and the economic impact of these modifications.

Sophia Humphreys, PharmD, MHA, BCBBS, explores the role of biosimilars in specialty pharmacy.

Cara Chang, PharmD, BCOP, and Alan Chin, PharmD, BCOP, engage in a comprehensive discussion about EGFR mutation therapies, relevant clinical trials, associated adverse reactions, and crucial strategies for optimizing patient outcomes in this specific subset of NSCLC patients.

Carrie Koenigsfeld, PharmD, FAPhA, provides a comprehensive overview of RSV vaccinations, including current clinical trials, their efficacy and safety data, and emphasizes the importance of addressing vaccine hesitancy by presenting evidence-based information to help patients make informed decisions about receiving the RSV vaccine.

Heather Moore, CPP, PharmD, recaps key topics from the 2023 ASCO meeting surrounding breast cancer treatment.

Ryan Haumschild, PharmD, MS, MBA, provides insights surrounding the utilization of PARP inhibitors and clinical pathways in ovarian cancer treatment.

Expert, Zahra Mahmoudjafari, PharmD, BCOP, DPLA shares insights on the expanding treatment landscape for CLL.

Tim Whitten, BSPharm, MBA, CEO & President of Taiho Oncology Inc discusses the critical impacts of pharmacists across the health care landscape.

Sponsored by Taiho Oncology Inc.

Neal Dave, PharmD, and Brandon Dyson, PharmD, BCOP, BCPS, share insights regarding the treatment landscape for patients with CML and Ph+ ALL.

Prophylactic treatment is critical to treatment management for patients diagnosed with hemophilia A.

Medical experts detail the current and evolving roles of BTK inhibitors in treatment of patients with relapsed/refractory mantle cell lymphoma.

Experts in hematology/oncology share key insight on the treatment of CLL, including the use of BTK inhibitors and the critical role of pharmacists in disease management.

Considerations regarding updates to chronic lymphocytic leukemia treatment algorithms based on novel and emerging therapies presented at the ASH 2021 annual meeting.

Pharmacist and provider perspective on BTK inhibitors for Waldenstrom macroglobulinemia.

Shared insight on unmet needs and recent innovations in the management of marginal zone lymphoma in the relapsed/refractory setting.

Joanna Lewis, PharmD, MBA, discusses practical considerations when selecting over-the-counter medications to treat common conditions pharmacists are often asked about and highlights some recommended medications from the Pharmacy Times’ OTC Guide